Unknown

Dataset Information

0

Structure-Based Optimization of 1,2,4-Triazole-3-Thione Derivatives: Improving Inhibition of NDM-/VIM-Type Metallo-β-Lactamases and Synergistic Activity on Resistant Bacteria.


ABSTRACT: The worldwide emergence and dissemination of Gram-negative bacteria expressing metallo-β-lactamases (MBLs) menace the efficacy of all β-lactam antibiotics, including carbapenems, a last-line treatment usually restricted to severe pneumonia and urinary tract infections. Nonetheless, no MBL inhibitor is yet available in therapy. We previously identified a series of 1,2,4-triazole-3-thione derivatives acting as micromolar inhibitors of MBLs in vitro, but devoid of synergistic activity in microbiological assays. Here, via a multidisciplinary approach, including molecular modelling, synthesis, enzymology, microbiology, and X-ray crystallography, we optimized this series of compounds and identified low micromolar inhibitors active against clinically relevant MBLs (NDM-1- and VIM-type). The best inhibitors increased, to a certain extent, the susceptibility of NDM-1- and VIM-4-producing clinical isolates to meropenem. X-ray structures of three selected inhibitors in complex with NDM-1 elucidated molecular recognition at the base of potency improvement, confirmed in silico predicted orientation, and will guide further development steps.

SUBMITTER: Bersani M 

PROVIDER: S-EPMC10747250 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Structure-Based Optimization of 1,2,4-Triazole-3-Thione Derivatives: Improving Inhibition of NDM-/VIM-Type Metallo-β-Lactamases and Synergistic Activity on Resistant Bacteria.

Bersani Matteo M   Failla Mariacristina M   Vascon Filippo F   Gianquinto Eleonora E   Bertarini Laura L   Baroni Massimo M   Cruciani Gabriele G   Verdirosa Federica F   Sannio Filomena F   Docquier Jean-Denis JD   Cendron Laura L   Spyrakis Francesca F   Lazzarato Loretta L   Tondi Donatella D  

Pharmaceuticals (Basel, Switzerland) 20231202 12


The worldwide emergence and dissemination of Gram-negative bacteria expressing metallo-β-lactamases (MBLs) menace the efficacy of all β-lactam antibiotics, including carbapenems, a last-line treatment usually restricted to severe pneumonia and urinary tract infections. Nonetheless, no MBL inhibitor is yet available in therapy. We previously identified a series of 1,2,4-triazole-3-thione derivatives acting as micromolar inhibitors of MBLs in vitro, but devoid of synergistic activity in microbiolo  ...[more]

Similar Datasets

| S-EPMC10650955 | biostudies-literature
| S-EPMC7151704 | biostudies-literature
| S-EPMC6658799 | biostudies-literature
| S-EPMC5807211 | biostudies-literature
| S-EPMC9216179 | biostudies-literature
| S-EPMC3379377 | biostudies-literature
| S-EPMC6326847 | biostudies-literature
| S-EPMC2961480 | biostudies-literature
| S-EPMC3569223 | biostudies-literature
| S-EPMC2493107 | biostudies-literature